SG11201602265PA - A selective inhibitor of phosphatidylinositol 3-kinase-gamma - Google Patents

A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Info

Publication number: SG11201602265PA
Authority: SG; Singapore
Prior art keywords: phosphatidylinositol; kinase; gamma; selective inhibitor; inhibitor
Prior art date: 2013-09-25

Application number

SG11201602265PA

Inventor

Michael John Boyd

Alex Aronov

Hardwin O'dowd

Jeremy Green

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-25

Filing date

2014-09-25

Publication date

2016-04-28

2014-09-25 Application filed by Vertex Pharma filed Critical Vertex Pharma

2016-04-28 Publication of SG11201602265PA publication Critical patent/SG11201602265PA/en

Links

229940124639 Selective inhibitor Drugs 0.000 title 1
150000003905 phosphatidylinositols Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG11201602265PA 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma SG11201602265PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361882473P	2013-09-25	2013-09-25
PCT/US2014/057499 WO2015048318A1 (en)	2013-09-25	2014-09-25	A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Publications (1)

Publication Number	Publication Date
SG11201602265PA true SG11201602265PA (en)	2016-04-28

Family

ID=51795739

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201602265PA SG11201602265PA (en)	2013-09-25	2014-09-25	A selective inhibitor of phosphatidylinositol 3-kinase-gamma
SG10201802061TA SG10201802061TA (en)	2013-09-25	2014-09-25	A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201802061TA SG10201802061TA (en)	2013-09-25	2014-09-25	A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Country Status (18)

Country	Link
US (1)	US10301304B2 (en)
EP (2)	EP3412668B1 (en)
JP (1)	JP6340416B2 (en)
KR (1)	KR20160058950A (en)
CN (1)	CN105722838B (en)
AU (1)	AU2014324873B2 (en)
BR (1)	BR112016006388A2 (en)
CA (1)	CA2925601C (en)
CL (1)	CL2016000695A1 (en)
ES (2)	ES2785053T3 (en)
HK (1)	HK1223620A1 (en)
IL (1)	IL244742A0 (en)
MX (1)	MX2016003823A (en)
RU (2)	RU2018142605A (en)
SG (2)	SG11201602265PA (en)
UA (1)	UA117032C2 (en)
WO (1)	WO2015048318A1 (en)
ZA (1)	ZA201702252B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
BR112016007467B1 (en)	2013-10-04	2022-09-20	Infinity Pharmaceuticals, Inc	HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN106456628A (en)	2014-03-19	2017-02-22	无限药品股份有限公司	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6786529B2 (en) *	2015-06-29	2020-11-18	バイオメッドバレーディスカバリーズ，インコーポレイティド	Combination of LPT-723 and Immune Checkpoint Inhibitors and Methods of Treatment
MX2018003058A (en)	2015-09-14	2018-08-01	Infinity Pharmaceuticals Inc	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same.
WO2017153527A1 (en) *	2016-03-10	2017-09-14	Astrazeneca Ab	Novel inhibitors of phosphatidylinositol 3-kinase gamma
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2020210379A1 (en)	2019-04-10	2020-10-15	Hangzhou Zhengxiang Pharmaceuticals Co., Ltd.	Phosphatidylinositol 3-kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR071717A1 (en) *	2008-05-13	2010-07-07	Array Biopharma Inc	PIRROLO [2,3-B] CHK1 AND CHK2 QUINASE INHIBITING PIRIDINS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE THEM AND USE OF THE SAME IN THE TREATMENT AND PREVENTION OF CANCER.
UY32582A (en) *	2009-04-28	2010-11-30	Amgen Inc	3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE
JP5721187B2 (en) *	2009-12-22	2015-05-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Isoindolinone inhibitor of phosphatidylinositol 3-kinase

2014
- 2014-09-25 EP EP18180366.9A patent/EP3412668B1/en active Active
- 2014-09-25 RU RU2018142605A patent/RU2018142605A/en unknown
- 2014-09-25 UA UAA201604461A patent/UA117032C2/en unknown
- 2014-09-25 KR KR1020167010907A patent/KR20160058950A/en not_active Application Discontinuation
- 2014-09-25 CN CN201480060785.XA patent/CN105722838B/en not_active Expired - Fee Related
- 2014-09-25 CA CA2925601A patent/CA2925601C/en active Active
- 2014-09-25 RU RU2016115726A patent/RU2675814C2/en not_active IP Right Cessation
- 2014-09-25 SG SG11201602265PA patent/SG11201602265PA/en unknown
- 2014-09-25 US US15/024,698 patent/US10301304B2/en active Active
- 2014-09-25 AU AU2014324873A patent/AU2014324873B2/en not_active Ceased
- 2014-09-25 ES ES18180366T patent/ES2785053T3/en active Active
- 2014-09-25 ES ES14789651.8T patent/ES2687593T3/en active Active
- 2014-09-25 BR BR112016006388A patent/BR112016006388A2/en not_active Application Discontinuation
- 2014-09-25 SG SG10201802061TA patent/SG10201802061TA/en unknown
- 2014-09-25 MX MX2016003823A patent/MX2016003823A/en unknown
- 2014-09-25 JP JP2016516904A patent/JP6340416B2/en not_active Expired - Fee Related
- 2014-09-25 EP EP14789651.8A patent/EP3049415B1/en active Active
- 2014-09-25 WO PCT/US2014/057499 patent/WO2015048318A1/en active Application Filing
2016
- 2016-03-23 IL IL244742A patent/IL244742A0/en unknown
- 2016-03-24 CL CL2016000695A patent/CL2016000695A1/en unknown
- 2016-10-17 HK HK16111963.2A patent/HK1223620A1/en not_active IP Right Cessation
2017
- 2017-03-30 ZA ZA2017/02252A patent/ZA201702252B/en unknown

Also Published As

Publication number	Publication date
CL2016000695A1 (en)	2017-06-09
EP3412668A2 (en)	2018-12-12
ES2687593T3 (en)	2018-10-26
HK1223620A1 (en)	2017-08-04
CN105722838B (en)	2017-10-24
EP3049415B1 (en)	2018-07-04
UA117032C2 (en)	2018-06-11
EP3412668B1 (en)	2020-02-05
JP2016531861A (en)	2016-10-13
CN105722838A (en)	2016-06-29
RU2675814C2 (en)	2018-12-25
BR112016006388A2 (en)	2017-08-01
RU2018142605A (en)	2019-02-04
CA2925601C (en)	2022-11-01
ZA201702252B (en)	2019-06-26
CA2925601A1 (en)	2015-04-02
MX2016003823A (en)	2016-08-01
AU2014324873B2 (en)	2018-11-08
IL244742A0 (en)	2016-04-21
EP3049415A1 (en)	2016-08-03
US10301304B2 (en)	2019-05-28
EP3412668A3 (en)	2018-12-19
SG10201802061TA (en)	2018-05-30
WO2015048318A1 (en)	2015-04-02
US20160214980A1 (en)	2016-07-28
KR20160058950A (en)	2016-05-25
RU2016115726A3 (en)	2018-06-20
ES2785053T3 (en)	2020-10-05
JP6340416B2 (en)	2018-06-06
AU2014324873A1 (en)	2016-04-21
RU2016115726A (en)	2017-10-30

Publication	Publication Date	Title
HK1248217A1 (en)	2018-10-12	Solid forms of a selective cdk4/6 inhibitor
HK1220968A1 (en)	2017-05-19	Phosphatidylinositol 3-kinase inhibitors 3-
HK1214818A1 (en)	2016-08-05	Selective hdac3 inhibitors hdac3
EP2970340A4 (en)	2016-10-19	Beta-lactamase inhibitors
HK1223620A1 (en)	2017-08-04	A selective inhibitor of phosphatidylinositol 3-kinase-gamma 3--
EP2943204A4 (en)	2016-11-09	Beta-lactamase inhibitors
EP2943901A4 (en)	2016-10-19	Application for monitoring a property of a surface
EP2948458A4 (en)	2016-07-27	Btk inhibitors
EP2948450A4 (en)	2016-11-09	Metalloenzyme inhibitor compounds
EP2948431A4 (en)	2016-10-26	Btk inhibitors
HK1216531A1 (en)	2016-11-18	Novel inhibitors
GB201317609D0 (en)	2013-11-20	Inhibitor compounds
IL242803A0 (en)	2016-02-01	Dihydropyridinone mgat2 inhibitors
GB201314578D0 (en)	2013-09-25	Bicyclic inhibitors
HK1222339A1 (en)	2017-06-30	Inhibitors of metallo-ss-lactamase-enzymes --
HK1215168A1 (en)	2016-08-19	Pentosidine production inhibitor
HK1221159A1 (en)	2017-05-26	Inhibitors of metastasis
IL245386A0 (en)	2016-06-30	Crystalline beta-lactamase inhibitor
EP2959896A4 (en)	2016-08-17	Inhibitor of tprotein phosphorylation
GB201321328D0 (en)	2014-01-15	Inhibitor compounds
GB201305503D0 (en)	2013-05-08	Inhibitor
GB201307906D0 (en)	2013-06-12	Corrosion inhibitor